Swedbank’s Esperion Therapeutics ESPR Stock Holding History

Swedbank’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-217,000	Closed	-$1.01M	–	752
2022 Q1	$1.01M	Hold	217,000	–	–	﹤0.01%	677
2021 Q4	$1.08M	Hold	217,000	–	–	﹤0.01%	686
2021 Q3	$2.61M	Hold	217,000	–	–	﹤0.01%	620
2021 Q2	$4.59M	Hold	217,000	–	–	0.01%	565
2021 Q1	$6.09M	Buy	+217,000	New	+$6.4M	0.01%	518

Other funds holding ESPR

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Swedbank's ESPR Position: Q2 2022 in Review

Swedbank sold out of Esperion Therapeutics (ESPR) in Q2 2022, closing a stake of 217,000 shares — an estimated $1.01M sold.

Swedbank first reported a position in ESPR in Q1 2021 and held it in 5 quarters. The position peaked at $6.09M in Q1 2021. 136 funds tracked by Wall St. Rank hold ESPR as of Q2 2022.

Swedbank reported no remaining Esperion Therapeutics position as of Q2 2022 after selling out during the quarter.
Swedbank sold 217,000 Esperion Therapeutics shares in Q2 2022, an estimated $1.01M.
Swedbank first reported a position in Esperion Therapeutics in Q1 2021 and held it in 5 quarters.
Swedbank's Esperion Therapeutics position peaked at $6.09M in Q1 2021.
136 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2022.

Based on Swedbank's 13F filing for Q2 2022, filed 6 Dec 2024.